Search results

715 results

Sorted by Relevance . Sort by Date

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Clinical guidelines Remove Clinical guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter
Diagnostics guidance Remove Diagnostics guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter

Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]

Proposed [GID-TA10785] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]

Proposed [GID-TA10784] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegunigalsidase alfa for treating Fabry disease [ID3904]

Proposed [GID-TA10790] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]

Proposed [GID-TA10789] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]

Proposed [GID-TA10783] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nitisinone for treating alkaptonuria [ID2691]

Proposed [GID-TA10659] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: 22 December 2021

Type

Technology appraisal guidance

Status

Proposed
Dapagliflozin for treating chronic kidney disease [ID3866]

Proposed [GID-TA10808] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]

Proposed [GID-TA10738] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]

Proposed [GID-TA10749] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: 10 August 2022

Type

Technology appraisal guidance

Status

Proposed
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Proposed [GID-TA10753] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active ankylosing spondylitis [ID3848]

Proposed [GID-TA10735] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lasmiditan for treating acute migraine [ID3759]

Proposed [GID-TA10807] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Proposed [GID-TA10637] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Proposed [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remdesivir for treating COVID-19 [ID3808]

Proposed [GID-TA10721] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Proposed [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bupivacaine–meloxicam for treating postoperative pain [ID2728]

Proposed [GID-TA10716] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating hypereosinophilic syndrome [ID3749]

Proposed [GID-TA10755] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]

Proposed [GID-TA10767] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]

Proposed [GID-TA10768] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]

Proposed [GID-TA10770] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Foscarbidopa–foslevodopa for treating motor fluctuations in Parkinson's disease [ID3876]

Proposed [GID-TA10772] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

Proposed [GID-TA10773] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]

Proposed [GID-TA10774] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]

Proposed [GID-TA10775] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]

Proposed [GID-TA10776] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]

Proposed [GID-TA10777] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]

Proposed [GID-TA10778] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

Proposed [GID-TA10779] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

Proposed [GID-TA10715] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

Proposed [GID-TA10717] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

Proposed [GID-TA10718] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed